News

Conquering Aggressive Sarcoma: The Promise of Engineered T-Cells

Research Advances /

Sarcomas, a rare and aggressive category of over 100 connective tissue malignancies, present a significant challenge due to high metastasis rates and resistance to standard therapies like conventional chemotherapy and first-generation checkpoint inhibitors. A major breakthrough is occurring with Adoptive Cell Therapy (ACT), where a patient’s immune cells are genetically engineered to target cancer. Notably, the […]

Conquering Aggressive Sarcoma: The Promise of Engineered T-Cells Read More »

Stopping the Spread: EZH2 Inhibitors Thwart Aggressive Breast Cancer Metastasis

Targeted Therapy /

A new study from Weill Cornell Medicine reveals that the enzyme EZH2 drives chromosomal instability in triple-negative breast cancer (TNBC), promoting metastasis. Researchers found that overproduction of EZH2 silences the gene tankyrase 1, causing accumulation of CPAP and abnormal chromosome segregation during cell division. This faulty process enables cancer cells to spread aggressively to distant organs.

Stopping the Spread: EZH2 Inhibitors Thwart Aggressive Breast Cancer Metastasis Read More »

Radiation Matters: Updated Evidence on Pediatric Imaging and Cancer Risk

Technology Innovation /

Ionizing radiation from medical imaging, particularly CT scans, is a major source of radiation exposure for children in the U.S. and a known carcinogen linked to hematologic malignancies (blood cancers). The large RIC cohort study (3.7 million children in the U.S. and Canada) found a significant dose-response relationship between cumulative bone marrow radiation dose and cancer risk. A

Radiation Matters: Updated Evidence on Pediatric Imaging and Cancer Risk Read More »

Primary Vaginal Cancer: Etiology, Management, and Prognosis

Rare Cancers /

Primary vaginal cancer is rare (1%–2% of female genital tract cancers), strictly defined by the absence of prior/concurrent cervical or vulvar cancer. Increasing incidence in younger women is linked to HPV infection. The pathogenesis is largely HPV-dependent, progressing from HSIL to invasive cancer (2%−12% risk). Diagnosis requires biopsy and a thorough exam, typically after a patient presents

Primary Vaginal Cancer: Etiology, Management, and Prognosis Read More »

The Iron Kill-Switch: How Iron Forces Cancer Cells to Self-Destruct

Research Advances /

Researchers at Duke University found that blocking a key enzyme not only kills multiple myeloma (MM) cancer cells but also boosts the effectiveness of existing therapies. MM is an incurable blood cancer, and drug resistance is an increasing problem. The study, published in Blood, focused on ferroptosis, a natural form of cell death triggered by

The Iron Kill-Switch: How Iron Forces Cancer Cells to Self-Destruct Read More »

Common Nutritional Aid Shows Promise in Strengthening Cancer Therapy

Treatment /

A new study from University of Chicago, published in Cell Reports Medicine, suggests that zeaxanthin, a plant carotenoid known for eye health, may also boost the immune system’s ability to fight cancer. The compound enhances CD8+ T cells, the body’s tumor-killing immune cells, by stabilizing their T-cell receptor (TCR) complex, leading to stronger activation and

Common Nutritional Aid Shows Promise in Strengthening Cancer Therapy Read More »

Additional COVID-19 Vaccine Doses Significantly Protect Cancer Patients from Severe Outcomes

Immunotherapy /

Cancer patients are at high risk for severe COVID-19, making extra vaccine doses important. This study assessed their effectiveness using real-world data. In the monovalent booster period (up to August 2022), an additional dose reduced hospitalizations (29.2% effectiveness), with rates of 30.5 per 1,000 person-years in boosted patients compared to 41.9 in those with only

Additional COVID-19 Vaccine Doses Significantly Protect Cancer Patients from Severe Outcomes Read More »

Intercalated Avelumab with Chemotherapy in ES-SCLC: A Phase II Efficacy and Safety Study

Clinical Trails /

In Phase II study for extensive-stage small-cell lung cancer (ES-SCLC), the novel intercalated administration of the anti-PD-L1 inhibitor avelumab with platinum-etoposide chemotherapy (avelumab started after cycle 2) did not meet the primary endpoint of a 25% one-year progression-free survival (PFS), achieving 12.7% (median PFS: 5.8 months). Despite this, the treatment demonstrated high anti-tumor activity with an Objective Response

Intercalated Avelumab with Chemotherapy in ES-SCLC: A Phase II Efficacy and Safety Study Read More »

Superiority of pFLOT: Network Meta-Analysis Identifies Optimal Regimen for Resectable Gastric and GEJ Cancer

Treatment /

Gastroesophageal cancers, though relatively uncommon in the U.S., cause significant morbidity and mortality worldwide. For early-stage gastric and gastroesophageal junction (GEJ) adenocarcinoma, the primary goal is cure, achieved through multimodality treatment. Landmark trials demonstrated the benefits of perioperative chemotherapy, such as the MAGIC trial’s pECF regimen, and neoadjuvant chemoradiotherapy, like the CROSS trial’s nCROSS regimen.

Superiority of pFLOT: Network Meta-Analysis Identifies Optimal Regimen for Resectable Gastric and GEJ Cancer Read More »

Smoking Still the Top Killer: A Look at US Cancer Cases and Deaths in 2025

News /

Cancer remains the second leading cause of death in the U.S., with the COVID-19 pandemic exacerbating delays in diagnosis and potentially worsening disparities and mortality. In 2025, an estimated 2,041,910 new invasive cancer cases and 618,120 deaths are expected, with roughly one in three men and women likely to be diagnosed in their lifetime. Lung

Smoking Still the Top Killer: A Look at US Cancer Cases and Deaths in 2025 Read More »